About Whitehawk Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://ir.whitehawktx.com/
Frequently Asked Questions
What is the 52-week range for WHWK?
The 52-week high is $5.495 and the 52-week low is $1.86.
What is the P/E ratio for WHWK?
The P/E ratio data is currently unavailable.
What is the dividend yield for WHWK?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -53.89%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 99.42%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.84.
Analyst Recommendation Trends
Wall Street analyst consensus for WHWK over the last few months:
Latest WHWK News
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting mucin 16 (MUC16) as a durable therapeutic target and potential prognostic biomarker in ovarian cancer. These data will be presented at the International Gynecologic Cancer Society (IGCS) Annual Gl
Whitehawk Therapeutics Presents Two-Real World Analyses Supporting Mucin 16
MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed SettingsHigh MUC16 Expression Was Associated with Poor
Stifel Initiates Coverage On Whitehawk Therapeutics with Buy Rating, Announces Price Target of $9
Stifel analyst Dara Azar initiates coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with a Buy rating and announces Price Target of $9.
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Whitehawk Therapeutics, Inc. (WHWK) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 1:05 PM EDTCompany ParticipantsScott...
Reported Sunday, Whitehawk's Real-World Data Show PTK7 Expression Remains Stable After Standard-Of-Care Therapies, Reinforcing Rationale For HWK-007 In EGFR Wild-Type NSCLC
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as a Target in Second- or Later-Line EGFR NSCLCFindings Reinforce the Scientific Rationale for HWK-007, Whitehawk's
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting protein tyrosine kinase 7 (PTK7) as a durable and clinically relevant ADC target in patients with pretreated, EGFR wild-type non-small cell lung cancer (NSCLC). The data will be presented at the I
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody-drug conjugate (ADC) cancer treatments, today announced the appointment of Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Lennon David James | +193,957 | - | - |
| 2026-09-15 | Lennon David James | +193,957 | - | - |
| 2026-09-15 | Dugan Margaret | +81,250 | - | - |
| 2026-09-15 | Dugan Margaret | +81,250 | - | - |
| 2026-09-15 | Dornan David | +85,887 | - | - |
| 2026-09-15 | Dornan David | +85,887 | - | - |
| 2026-09-15 | BALL BRYAN | +91,633 | - | - |
| 2026-09-15 | BALL BRYAN | +91,633 | - | - |
| 2026-09-15 | Giacobello Scott M. | +118,476 | - | - |
| 2026-09-15 | Giacobello Scott M. | +118,476 | - | - |
| 2026-09-15 | Lennon David James | +193,957 | - | - |
| 2026-09-15 | Lennon David James | +193,957 | - | - |
| 2026-09-15 | Dugan Margaret | +81,250 | - | - |
| 2026-09-15 | Dugan Margaret | +81,250 | - | - |
| 2026-09-15 | Dornan David | +85,887 | - | - |
| 2026-09-15 | Dornan David | +85,887 | - | - |
| 2026-09-15 | BALL BRYAN | +91,633 | - | - |
| 2026-09-15 | BALL BRYAN | +91,633 | - | - |
| 2026-09-15 | Giacobello Scott M. | +118,476 | - | - |
| 2026-09-15 | Giacobello Scott M. | +118,476 | - | - |
| 2026-09-09 | Iyengar Vijay K | +76,080 | - | - |
| 2026-06-12 | Dalal Anupam | +38,040 | - | - |
| 2026-06-12 | Zhao Baiteng | +38,040 | - | - |
| 2026-06-12 | Desai Neil | +38,040 | - | - |
| 2026-06-12 | Avoro Capital Advisors LLC | +38,040 | - | - |
| 2026-06-12 | Reeve Emma | +38,040 | - | - |
| 2026-06-12 | Hirmand Mohammad | +38,040 | - | - |
| 2026-06-12 | Maroun Richard E | +38,040 | - | - |
| 2026-06-12 | Castelein Caley | +38,040 | - | - |
| 2026-05-14 | Dalal Anupam | +1,275,510 | $3.92 | $4,999,999 |
| 2026-05-14 | Lennon David James | +51,021 | $3.92 | $200,002 |
| 2026-05-14 | Dugan Margaret | +19,132 | $3.92 | $74,997 |
| 2026-05-14 | BALL BRYAN | +51,020 | $3.92 | $199,998 |
| 2026-05-14 | Giacobello Scott M. | +38,265 | $3.92 | $149,999 |
| 2026-05-14 | Castelein Caley | +2,072,756 | $8124996 | $16,841,134,208,976 |
| 2026-05-14 | Castelein Caley | +255,102 | $3.92 | $1,000,000 |
| 2026-05-12 | Avoro Capital Advisors LLC | +6,377,714 | $3.9199 | $25,000,001 |
| 2026-04-16 | Giacobello Scott M. | -141,600 | $4.13 | $584,808 |
| 2026-04-15 | Giacobello Scott M. | -77,000 | $3.86 | $297,220 |
| 2026-04-14 | BALL BRYAN | -92,460 | $3.64 | $336,554 |
| 2026-04-13 | BALL BRYAN | -26,389 | $3.46 | $91,306 |
| 2026-04-10 | BALL BRYAN | -6,596 | $3.43 | $22,624 |
| 2026-04-09 | BALL BRYAN | -50,000 | $3.57 | $178,500 |
| 2026-04-09 | Lennon David James | -14,500 | $3.38 | $49,010 |
| 2026-04-08 | Lennon David James | -63,945 | $3.4 | $217,413 |
| 2026-04-07 | Lennon David James | -94,087 | $3.43 | $322,718 |
| 2026-04-06 | Lennon David James | -102,395 | $3.51 | $359,406 |
| 2026-04-02 | Lennon David James | -26,858 | $3.48 | $93,466 |
| 2026-04-01 | Lennon David James | +831,148 | - | - |
| 2026-04-01 | Lennon David James | -775,828 | - | - |
| 2026-04-01 | Lennon David James | +775,828 | - | - |
| 2026-04-01 | Dugan Margaret | +283,157 | - | - |
| 2026-04-01 | Dornan David | +282,340 | - | - |
| 2026-04-01 | BALL BRYAN | +250,058 | - | - |
| 2026-04-01 | BALL BRYAN | -366,532 | - | - |
| 2026-04-01 | BALL BRYAN | +366,532 | - | - |
| 2026-04-01 | Giacobello Scott M. | +300,677 | - | - |
| 2026-04-01 | Giacobello Scott M. | -473,902 | - | - |
| 2026-04-01 | Giacobello Scott M. | +473,902 | - | - |
| 2026-03-02 | Lennon David James | -5,100 | $3.3096 | $16,879 |
| 2026-03-02 | BALL BRYAN | -1,834 | $3.3096 | $6,070 |
| 2026-03-02 | Giacobello Scott M. | -2,594 | $3.3096 | $8,585 |
| 2026-03-01 | Lennon David James | -16,250 | - | - |
| 2026-03-01 | Lennon David James | +16,250 | - | - |
| 2026-03-01 | BALL BRYAN | -5,000 | - | - |
| 2026-03-01 | BALL BRYAN | +5,000 | - | - |
| 2026-03-01 | Giacobello Scott M. | -6,750 | - | - |
| 2026-03-01 | Giacobello Scott M. | +6,750 | - | - |
| 2025-12-01 | Dugan Margaret | +55,309 | - | - |
| 2025-12-01 | Dugan Margaret | +650,000 | - | - |